News InDex craters on phase 3 ulcerative colitis failure InDex Pharmaceuticals has said it will abandon a phase 3 trial of its lead drug cobitolimod in moderate-to-severe ulcerative colitis, its only clinical-stage programme, wr
Events Partner Content STING & TLR Targeting Therapies Summit Investigating the cGAS-STING and TLR pathways
Digital Chaos & opportunity: Dr Adam Brown unpacks US health policy Dive into our video interview with Dr Adam Brown as he unpacks the chaos and opportunity shaping US health policy.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face